Cargando…

Amyloid‐β PET and CSF in an autopsy‐confirmed cohort

OBJECTIVE: Accumulation of amyloid‐β is among the earliest changes in Alzheimer’s disease (AD). Amyloid‐β positron emission tomography (PET) and Aβ (42) in cerebrospinal fluid (CSF) both assess amyloid‐β pathology in‐vivo, but 10–20% of cases show discordant (CSF+/PET− or CSF‐/PET+) results. The neu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reimand, Juhan, Boon, Baayla D. C., Collij, Lyduine E., Teunissen, Charlotte E., Rozemuller, Annemieke J. M., van Berckel, Bart N. M., Scheltens, Philip, Ossenkoppele, Rik, Bouwman, Femke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7664271/ https://www.ncbi.nlm.nih.gov/pubmed/33080124 http://dx.doi.org/10.1002/acn3.51195

Ejemplares similares

Discordant amyloid-β PET and CSF biomarkers and its clinical consequences
por: de Wilde, Arno, et al.
Publicado: (2019)

Why Is Amyloid-β PET Requested After Performing CSF Biomarkers?
por: Reimand, Juhan, et al.
Publicado: (2020)

PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases
por: Reimand, Juhan, et al.
Publicado: (2019)

Clinical outcomes up to 9 years after [(18)F]flutemetamol amyloid-PET in a symptomatic memory clinic population
por: Collij, Lyduine E., et al.
Publicado: (2023)

Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers
por: Ossenkoppele, Rik, et al.
Publicado: (2021)

Assessing Amyloid Pathology in Cognitively Normal Subjects Using (18)F-Flutemetamol PET: Comparing Visual Reads and Quantitative Methods
por: Collij, Lyduine E., et al.
Publicado: (2019)

Neuroinflammation is increased in the parietal cortex of atypical Alzheimer’s disease
por: Boon, Baayla D. C., et al.
Publicado: (2018)

Comparing CSF amyloid‐beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status
por: Willemse, Eline A. J., et al.
Publicado: (2021)

Is retinal vasculature a biomarker in amyloid proven Alzheimer's disease?
por: den Haan, Jurre, et al.
Publicado: (2019)

Amyloid imaging in clinical trials
por: Ossenkoppele, Rik, et al.
Publicado: (2013)

Amyloid imaging in prodromal Alzheimer's disease
por: Ossenkoppele, Rik, et al.
Publicado: (2011)

Visual assessment of [(18)F]flutemetamol PET images can detect early amyloid pathology and grade its extent
por: Collij, Lyduine E., et al.
Publicado: (2021)

Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline
por: Ebenau, Jarith L., et al.
Publicado: (2022)

Biomarker A+T−: is this Alzheimer’s disease or not? A combined CSF and pathology study
por: Vromen, Eleonora M, et al.
Publicado: (2022)

Regional amyloid accumulation predicts memory decline in initially cognitively unimpaired individuals
por: Collij, Lyduine E., et al.
Publicado: (2021)

Plasma biomarkers predict amyloid pathology in cognitively normal monozygotic twins after 10 years
por: den Braber, Anouk, et al.
Publicado: (2023)

Amyloid-driven disruption of default mode network connectivity in cognitively healthy individuals
por: Ingala, Silvia, et al.
Publicado: (2021)

Human cerebral vascular amyloid contains both antiparallel and parallel in-register Aβ40 fibrils
por: Irizarry, Brandon A., et al.
Publicado: (2021)

Amyloid-β, p-tau and reactive microglia are pathological correlates of MRI cortical atrophy in Alzheimer’s disease
por: Frigerio, Irene, et al.
Publicado: (2021)

Genetically identical twin-pair difference models support the amyloid cascade hypothesis
por: Coomans, Emma M, et al.
Publicado: (2023)

Regional [(18)F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease
por: Wolters, Emma E., et al.
Publicado: (2020)

Amyloid-beta and phosphorylated tau in post-mortem Alzheimer’s disease retinas
por: den Haan, Jurre, et al.
Publicado: (2018)

Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimer’s disease
por: Visser, Denise, et al.
Publicado: (2020)

Structural (dys)connectivity associates with cholinergic cell density in Alzheimer’s disease
por: Lin, Chen Pei, et al.
Publicado: (2022)

Retinal thickness as a potential biomarker in patients with amyloid-proven early- and late-onset Alzheimer's disease
por: den Haan, Jurre, et al.
Publicado: (2019)

Spatial-Temporal Patterns of β-Amyloid Accumulation: A Subtype and Stage Inference Model Analysis
por: Collij, Lyduine E., et al.
Publicado: (2022)

Can post-mortem MRI be used as a proxy for in vivo? A case study
por: Boon, Baayla D C, et al.
Publicado: (2019)

Different curcumin forms selectively bind fibrillar amyloid beta in post mortem Alzheimer’s disease brains: Implications for in-vivo diagnostics
por: den Haan, Jurre, et al.
Publicado: (2018)

Added value of amyloid PET in individualized risk predictions for MCI patients
por: van Maurik, Ingrid S., et al.
Publicado: (2019)

Combination of plasma amyloid beta((1-42/1-40)) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology
por: Verberk, Inge M. W., et al.
Publicado: (2020)

White matter microstructure disruption in early stage amyloid pathology
por: Collij, Lyduine E., et al.
Publicado: (2021)

Label-free vibrational imaging of different Aβ plaque types in Alzheimer’s disease reveals sequential events in plaque development
por: Röhr, Dominik, et al.
Publicado: (2020)

No difference in retinal fluorescence after oral curcumin intake in amyloid‐proven AD cases compared to controls
por: den Haan, Jurre, et al.
Publicado: (2022)

Genetically identical twins show comparable tau PET load and spatial distribution
por: Coomans, Emma M, et al.
Publicado: (2022)

[(11)C]PIB amyloid quantification: effect of reference region selection
por: Heeman, Fiona, et al.
Publicado: (2020)

Impact of cerebral blood flow and amyloid load on SUVR bias
por: Heeman, Fiona, et al.
Publicado: (2022)

The natural history of primary progressive aphasia: beyond aphasia
por: Ulugut, Hulya, et al.
Publicado: (2021)

Amyloid-β and APOE genotype predict memory decline in cognitively unimpaired older individuals independently of Alzheimer’s disease polygenic risk score
por: Tomassen, Jori, et al.
Publicado: (2022)

Multitracer model for staging cortical amyloid deposition using PET imaging
por: Collij, Lyduine E., et al.
Publicado: (2020)

Plasma amyloid-β oligomerization assay as a pre-screening test for amyloid status
por: Babapour Mofrad, Rosha, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6dgqvsiml0ll0if242jau2ftiv